Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Portage Biotech Inc (PRTG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PRTG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $140
1 Year Target Price $140
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.96% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.05M USD | Price to earnings Ratio - | 1Y Target Price 140 |
Price to earnings Ratio - | 1Y Target Price 140 | ||
Volume (30-day avg) 1 | Beta 0.6 | 52 Weeks Range 2.30 - 15.82 | Updated Date 08/15/2025 |
52 Weeks Range 2.30 - 15.82 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -92.69% | Return on Equity (TTM) -541.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18315873 | Price to Sales(TTM) - |
Enterprise Value 18315873 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.02 | Shares Outstanding 2278620 | Shares Floating 1454855 |
Shares Outstanding 2278620 | Shares Floating 1454855 | ||
Percent Insiders 37.1 | Percent Institutions 4.6 |
Upturn AI SWOT
Portage Biotech Inc
Company Overview
History and Background
Portage Biotech Inc. (PRTG) is a clinical-stage immuno-oncology company founded in 2012, focused on developing therapies targeting the innate immune system. It has acquired and incubated multiple biotechnology assets.
Core Business Areas
- Immuno-oncology: Developing novel therapies to treat cancer by modulating the immune system.
Leadership and Structure
Dr. Ian McHale serves as the CEO. The company operates with a decentralized structure, managing a portfolio of subsidiary companies and programs.
Top Products and Market Share
Key Offerings
- PORT-2: PORT-2 is a liposomal formulation of dianhydrogalactitol (DAG) in clinical development for cancer. Market share data is difficult to determine due to the early stage. Competitors include companies developing chemotherapy drugs and other immuno-oncology agents.
- PORT-3: PORT-3 is an invariant Natural Killer T (iNKT) cell agonist in clinical development for cancer. Market share data is difficult to determine due to the early stage. Competitors include other companies developing iNKT cell agonists.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing rapid growth, driven by advances in understanding the interplay between the immune system and cancer.
Positioning
Portage Biotech is positioned as an early-stage innovator in the immuno-oncology space, with a portfolio of novel therapies in clinical development.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars. Portage is positioned to capture a share of this market with successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Diverse portfolio of immuno-oncology assets
- Strong scientific team
- Early-stage innovation focus
Weaknesses
- Limited financial resources
- Early-stage clinical development risks
- Reliance on external funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Acquisition of promising new assets
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRNA
- BMY
- PFE
Competitive Landscape
Portage Biotech faces significant competition from larger, well-established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the clinical pipeline and fluctuating stock price.
Future Projections: Future growth depends on successful clinical trial outcomes and securing partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for PORT-2 and PORT-3, and exploring new therapeutic targets.
Summary
Portage Biotech is a high-risk, high-reward investment. It boasts an innovative portfolio of immuno-oncology assets and a strong team. However, it faces significant financial challenges and clinical trial risks. Successfully navigating these challenges will determine its future prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Portage Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-25 | CEO & Director Mr. Alexander Pickett | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.portagebiotech.com |
Full time employees 3 | Website https://www.portagebiotech.com | ||
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.